Clinical Trial Update: Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations [Phase 1]

View source ↗

Summary

A Phase 1 safety and proof-of-concept trial evaluating oral QLT091001 in individuals with Leber congenital amaurosis or retinitis pigmentosa due to RPE65 or LRA…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Congenital Amaurosis
• Retinitis Pigmentosa

Drugs mentioned

• QLT091001 (retinoid)

Snippet

Sponsor: QLT Inc. | Conditions: LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa) | Phase 1 | Status: COMPLETED